Related Experiment Video
Updated: Jan 22, 2026

Activation and Measurement of NLRP3 Inflammasome Activity Using IL-1β in Human Monocyte-derived Dendritic Cells
Published on: May 22, 2014
Tim-4 Inhibits NLRP3 Inflammasome via the LKB1/AMPKα Pathway in Macrophages
Wen Liu1, Fuxiang Bai2, Hongxing Wang1
1Department of Immunology, Key Laboratory for Experimental Teratology of Ministry of Education, Shandong Provincial Key Laboratory of Infection and Immunology, School of Basic Medical Sciences, Shandong University, Jinan, Shandong 250012, People's Republic of China.
Abstract:
Nonalcoholic fatty liver disease (NAFLD), characterized by excessive inflammation and lipid deposition, is one of the most common metabolic liver diseases. The expression of NLRP3 inflammasome in macrophages is significantly increased in NAFLD, and its activation aggravates NAFLD greatly. Tim-4, as the phosphatidylserine (PS) receptor, is expressed highly in macrophages, and macrophage Tim-4 inhibits inflammation under various conditions of immune activation. However, the precise role of Tim-4 in NLRP3 inflammasome regulation and NAFLD pathogenesis remains completely unknown. Using NAFLD mice models, we confirmed that the expression of Tim-4 was increased in liver tissues by Western blot, real-time PCR, immunohistochemistry, and immunofluorescence, especially higher expression in liver macrophages, and Tim-4 knockout mice displayed more severe liver inflammation and hepatic steatosis than controls in NAFLD mice model. In vitro, we found that Tim-4 could inhibit NLRP3 inflammasome activation, and the inhibition was dependent on PS binding domain in the IgV domain. Mechanistically, Tim-4 induced the degradation of NLRP3 inflammasome components through activating AMPKα-mediated autophagy. Specifically, Tim-4 promoted AMPKα phosphorylation by interacting with LKB1 and AMPKα. In addition, PS binding motif was responsible for Tim-4-mediated AMPKα and LKB1 interaction. In conclusion, NAFLD microenvironments upregulate Tim-4 expression in macrophages, and elevated Tim-4, in turn, suppresses NLRP3 inflammasome activation by activating LKB1/AMPKα-mediated autophagy, thereby ameliorating the release of IL-1β and IL-18. Collectively, this study unveils the novel function of Tim-4 in suppressing NLRP3 inflammasome, which would shed new lights on intervention of NAFLD or inflammatory liver diseases by targeting Tim-4.
Insights
Tim-4, a phosphatidylserine receptor, suppresses NLRP3 inflammasome activation in nonalcoholic fatty liver disease (NAFLD). Upregulated Tim-4 in NAFLD macrophages activates autophagy, reducing liver inflammation and steatosis.
Area of Science:
- Hepatology
- Immunology
- Molecular Biology
Background:
- Nonalcoholic fatty liver disease (NAFLD) involves liver inflammation and lipid deposition.
- NLRP3 inflammasome activation in macrophages exacerbates NAFLD.
- Tim-4, a phosphatidylserine receptor on macrophages, typically inhibits inflammation.
Purpose of the Study:
- To investigate the role of Tim-4 in NLRP3 inflammasome regulation and NAFLD pathogenesis.
- To elucidate the mechanism by which Tim-4 influences NAFLD.
Main Methods:
- Utilized NAFLD mouse models with Western blot, real-time PCR, immunohistochemistry, and immunofluorescence.
- Performed in vitro experiments to assess Tim-4's effect on NLRP3 inflammasome activation.
- Investigated the interaction between Tim-4, LKB1, and AMPKα.
Main Results:
- Tim-4 expression is increased in NAFLD liver tissues, particularly in macrophages.
- Tim-4 knockout mice showed exacerbated liver inflammation and steatosis.
- Tim-4 inhibited NLRP3 inflammasome activation via LKB1/AMPKα-mediated autophagy, dependent on its PS binding domain.
Conclusions:
- NAFLD microenvironments upregulate Tim-4 in macrophages.
- Elevated Tim-4 suppresses NLRP3 inflammasome activation and ameliorates NAFLD.
- Tim-4 represents a potential therapeutic target for NAFLD and inflammatory liver diseases.
More Related Videos
Related Concept Videos
Feedback Inhibition
C4 Pathway and CAM
C4 Pathway
The C4 pathway is used by plants such as...
Enzyme Inhibition
Other Glycolytic Pathways
Inhibition of Cdk Activity
Respiration Pathways

